达格列净对心力衰竭患者生活质量及预后的影响

doi:10.3969/j.issn.1006-6233.2023.11.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1185 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of dapagliflozin treatment on cardiac function,quality of life and prognosis of patients with heart failure. Methods: A total of 250 patients with heart failure were randomly divided into experimental group and control group,of which 157 patients in the control group were treated with cardiac rehabilitation exercise and conventional anti-heart failure therapy,and 93 patients in the experimental group were treated with dapagliflozin 10mg once a day on the basis of the control group.Two groups were compared before and after treatment with serum N-terminal precursor brain natriuretic peptide (NT-proBNP),percentage of neutrophils (N%),hemoglobin (Hb),creatinine (Cr),left ventricular ejection fraction (LVEF),left ventricular end-diastolic diameter (LVEDD),Left ventricular wall relative thickness (RWT),6-minute walk experiment (6MWD),Minnesota Chronic Heart Failure Quality of Life Questionnaire (MLHFQ),and follow-up readmission rate and mortality within 6 months,and the differences of various indicators were compared and analyzed. Results: There were no significant differences between in NT-proBNP,N%,Hb,Cr,LVEF,LVEDD,RWT,6MWD and MLHFQ in the pre-intervention experimental group and control group (P>0.05). After the intervention,the serum NT-proBNP level,serum Cr level,LVEDD and 6MWD scores decreased (P<0.05),LVEF value and MLHFQ increased (P<0.05),all indicators after intervention in the experimental group were better than those in the control group. All patients were followed up.The readmission rates within six months in the experimental group and the control group were 16.13% and 22.93%,respectively.The difference was statistically significant between the two groups (P<0.05).The cardiogenic mortality rates of the two groups were 2.2% and 8.2%,respectively,and the difference between the two groups was statistically significant (P<0.05).There was no significant difference in the incidence of myocardial infarction and renal dysfunction between the two groups (P>0.05). Conclusion: Cardiac rehabilitation and dapagliflozin combination therapy can significantly improve the cardiopulmonary function and quality of life of patients,and is of great help to improve the long-term prognosis of patients with heart failure.

Key words： Heart failure Cardiac rehabilitation exercise Dapagliflozin Efficacy evaluation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FU Yizi
	WU Huizhi
	YU Haixia
	et al

Cite this article:

FU Yizi,WU Huizhi,YU Haixia, et al. Effect of Dapagliflozin on Quality of Life and Prognosis in Patients with Heart Failure[J]. HeBei Med, 2023, 29(11): 1911-1915.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.11.030 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I11/1911

[1] 中国医师协会心血管内科医师分会心力衰竭学组,中国心衰中心联盟专家委员会.中国心力衰竭诊断与治疗质量评价和控制指标专家共识[J].中国医学前沿杂志(电子版)/Chinese Journal of the Frontiers of Medical Science(Electronic Version),2021,13(3):52-62.
[2] Tomasoni D,Adamo M,Anker M S,et al.Heart failure in the last year:progress and perspective[J].ESC Heart Failure,2020,7(6):3505-3530.
[3] Bozkurt B,Coats A J S,Tsutsui H,et al.Universal definition and classification of heart failure[J].Journal of Cardiac Failure,2021,27(4):387-413.
[4] Fleming G A,Petrie J R,Bergenstl R M,et al.Diabetes digital app technology:benefits,challenges,and recommendations.A consensus report by the european association for the study of diabetes (EASD) and the American diabetes association (ADA) diabetes technology working Group[J].Diabetes Care,2020,43(1):250-260.
[5] Rossing P,Inzucchi S E,Vart P,et al.Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure:pooled analysis of the DAPA-CKD and DAPA-HF trials[J].The Lancet Diabetes & Endocrinology,2022,10(1):24-34.
[6] Verma S,Dhingra N K,Butler J,et al.Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced):a post-hoc analysis of a randomised,double-blind trial[J].The Lancet Diabetes & Endocrinology,2022,10(1):35-45.
[7] Docherty K F,Mcmurray J J V.SOLOIST-WHF and updated meta-analysis:sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure[J].European Journal of Heart Failure,2020,23(1):27-30.
[8] Sunamura M,Ter hoeve N,Van Den Berg-emons R J G,et al.Patients who do not complete cardiac rehabilitation have an increased risk of cardiovascular events during long-term follow-up[J].Netherlands Heart Journal,2020,28(9):460-466.
[9] Pepera G,Sandercock G R H.Incremental shuttle walking test to assess functional capacity in cardiac rehabilitation:a narrative review[J].International Journal of Therapy and Rehabilitation,2022,29(5):1-10.
[10] Santulli G,Wang X,Mone P.Updated ACC/AHA/HFSA 2022 guidelines on heart failure:what is new? From epidemiology to clinical management[J].European Heart Journal-Cardiovascular Pharmacotherapy,2022,8(5):23-24.